Şükrü Tüzmen

Prof. Dr. Şükrü Tüzmen

Faculty of Dentistry, Eastern Mediterranean University, Famagusta, Ammóchostos, Cyprus

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2004 in Nature Genetics
Verified
Journal Article
Closed access
PHPia Huusko
Pia Huusko
DPDamaris Ponciano-Jackson
Damaris Ponciano-Jackson
MWMaija Wolf
Maija Wolf
JKJeff A Kiefer
Jeff A Kiefer
DADavid O Azorsa
David O Azorsa
SMSpyro Mousses
Spyro Mousses

5 September 2011 in Oncogene
Verified
Journal Article
Closed access
AMA Mamo
A Mamo
LCL Cavallone
L Cavallone
Şükrü TüzmenŞükrü Tüzmen
Şükrü Tüzmen
CCC Chabot
C Chabot
CFC Ferrario
C Ferrario
MBM Basik
M Basik

1 March 2007 in Cancer Research
Verified
Journal Article
Closed access
PDF file
RKRiina Kuuselo
Riina Kuuselo
KSKimmo Savinainen
Kimmo Savinainen
DADavid O. Azorsa
David O. Azorsa
GBGargi D. Basu
Gargi D. Basu
RKRitva Karhu
Ritva Karhu
AKAnne Kallioniemi
Anne Kallioniemi
Pancreatic cancer is a highly aggressive disease characterized by poor prognosis and vast genetic instability. Recent microarray-based, genome-wide surveys have identified multiple recurrent copy number aberrations in pancreatic cancer; however, the target genes are, for the most part, unknown. Here, we characterized the 19q13 amplicon in pancreatic cancer to identify putative new drug targets. Copy number increases at 19q13 were quantitated in 16 pancreatic cancer cell lines and 31 primary tumors by fluorescence in situ hybridization. Cell line copy number data delineated a 1.1 Mb amplicon, the presence of which was also validated in 10% of primary pancreatic tumors. Comprehensive expression analysis by quantitative real-time reverse transcription-PCR indicated that seven transcripts within this region had consistently elevated expression levels in the amplified versus nonamplified cell lines. High-throughput loss-of-function screen by RNA interference was applied across the amplicon to identify genes whose down-regulation affected cell viability. This screen revealed five genes whose down-regulation led to significantly decreased cell viability in the amplified PANC-1 cells but not in the nonamplified MiaPaca-2 cells, suggesting the presence of multiple biologically interesting genes in this region. Of these, the transcriptional regulator intersex-like (IXL) was consistently overexpressed in amplified cells and had the most dramatic effect on cell viability. IXL silencing also resulted in G0-G1 cell cycle arrest and increased apoptosis in PANC-1 cells. These findings implicate IXL as a novel amplification target gene in pancreatic cancer and suggest that IXL is required for cancer cell survival in 19q13-amplified tumors. [Cancer Res 2007;67(5):1943–9]

1 May 2008 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
GBGargi D. Basu
Gargi D. Basu
DADavid O. Azorsa
David O. Azorsa
JKJeffrey A. Kiefer
Jeffrey A. Kiefer
ARAngela M. Rojas
Angela M. Rojas
Şükrü TüzmenŞükrü Tüzmen
Şükrü Tüzmen
SMSpyro Mousses
Spyro Mousses

1 November 2017 in Pharmacogenomics and Personalized Medicine
Verified
Journal Article
Open access
PDF file
MRMalak Rizk
Malak Rizk
Şükrü TüzmenŞükrü Tüzmen
Şükrü Tüzmen
RNA interference (RNAi) is a naturally existing endogenous mechanism for posttranscriptional gene regulation, nowadays commonly utilized for functional characterization of genes and development of potential treatment strategies for diseases. RNAi-based studies for therapy, after being examined for over a decade, are finally in the pipeline for developing a potential treatment for the mutated transthyretin (TTR) gene, which gives rise to a dysfunctional TTR protein. This dysfunctional protein causes TTR amyloidosis (ATTR), an inherited, progressively incapacitating, and often fatal genetic disorder. TTR is a protein produced in the liver, and functions as a carrier for retinol-binding protein and also thyroxine. This protein facilitates the transport of vitamin A around the human body. A mutation or misprint in the code of this protein results in an abnormal folding of the protein. Therefore, not only does the transportation of the vitamin A become disabled, but also there will be formation of clusters called amyloid deposits, which attack the heart and the nerves causing some patients to be unconditionally bound to bed. ATTR is a hereditary autosomal dominant disease with a 50% chance of inheritance by offspring, even with just one of the parents having a single defective allele of this gene. Alnylam Pharmaceuticals worked on the concept of RNAi therapy for years, which led to the introduction of lipid nanoparticles encircling small interfering RNAs. The drug showed extremely positive results since the first trial, and a great percentage of defective protein reduction. This drug was later named Patisiran.